Bod Australia implements LOI with Tilman S.A; stock up on ASX

Bod Australia Limited (ASX: BDA), based in Double Bay, develops, produces and commercialises plant-based extracts including medicinal cannabis, health and supplement products, as well as skin-care solutions across the Australian market. The company has a research collaboration agreement with Cannabis Access Clinics.

On March 11, the company announced to have executed a letter of intent (LOI) with its long-term partner Tilman S.A., a Belgian-based natural medicine manufacturer, which possesses more than 60 years of experience in quality management, research, development as well as a great global business acumen evident from its delivery of yearly sales in excess of EUR 35 million.

As per the agreement, Tilman will distribute Bod’s cannabis products namely MediCabilis and NutraCabilis, to its established clients (pharmacies and retailers) in Belgium and Luxembourg.

by